Caliway Biopharmaceuticals Co. L
6919
Rang in aandelen
#4341
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Aandeelprijs
$2.29
Marktkapitalisatie
$3.56B
Verandering (1 dag)
-2.50%
Verandering (1 jaar)
-57.22%
Land
TW
Handel Caliway Biopharmaceuticals Co. L (6919)
Categorie
Healthcare
Koersgeschiedenis voor Caliway Biopharmaceuticals Co. L (6919)
Hoogste slotkoers: $2.44 op 2026-10-01
Laagste slotkoers: $0.20 op 2022-12-01
Laagste slotkoers: $0.20 op 2022-12-01
Koersgeschiedenis van Caliway Biopharmaceuticals Co. L van 2022 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -25.32% |
| 2025 | 190.26% |
| 2024 | 181.33% |
| 2023 | 210.73% |
| 2022 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $536.98 | 25.92% |
US
|
|
| $224.77 | 737.11% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.75 | 7.69% |
NL
|
